Oruka Therapeutics ABIO Stock
Oruka Therapeutics Price Chart
Oruka Therapeutics ABIO Financial and Trading Overview
| Oruka Therapeutics stock price | 28.8 USD |
| Previous Close | 2.04 USD |
| Open | 2.02 USD |
| Bid | 0 USD x 3100 |
| Ask | 0 USD x 900 |
| Day's Range | 2.02 - 2.11 USD |
| 52 Week Range | 1.85 - 2.7 USD |
| Volume | 30.89K USD |
| Avg. Volume | 25.92K USD |
| Market Cap | 30.26M USD |
| Beta (5Y Monthly) | 1.366901 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ABIO Valuation Measures
| Enterprise Value | -11096308 USD |
| Trailing P/E | N/A |
| Forward P/E | -0.23863634 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.74653393 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 1.356 |
Trading Information
Oruka Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.366901 |
| 52-Week Change | -10.63% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 2.7 USD |
| 52 Week Low | 1.85 USD |
| 50-Day Moving Average | 2.05 USD |
| 200-Day Moving Average | 2.15 USD |
ABIO Share Statistics
| Avg. Volume (3 month) | 25.92K USD |
| Avg. Daily Volume (10-Days) | 25.01K USD |
| Shares Outstanding | 14.41M |
| Float | 10.3M |
| Short Ratio | 10.47 |
| % Held by Insiders | 1.02% |
| % Held by Institutions | 44.96% |
| Shares Short | 272.61K |
| Short % of Float | 2.65% |
| Short % of Shares Outstanding | 1.89% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:18 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -11.013% |
| Return on Equity (ttm) | -18.084% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -8182000 USD |
| Net Income Avi to Common (ttm) | -8000000 USD |
| Diluted EPS (ttm) | -0.53 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 40.85M USD |
| Total Cash Per Share (mrq) | 2.84 USD |
| Total Debt (mrq) | 357K USD |
| Total Debt/Equity (mrq) | 0.88 USD |
| Current Ratio (mrq) | 32.94 |
| Book Value Per Share (mrq) | 2.813 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8209000 USD |
| Levered Free Cash Flow (ttm) | -5234625 USD |
Profile of Oruka Therapeutics
| Country | United States |
| State | CO |
| City | Westminster |
| Address | 10170 Church Ranch Way |
| ZIP | 80021 |
| Phone | 720 940 2200 |
| Website | https://www.arcabio.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.
Q&A For Oruka Therapeutics Stock
What is a current ABIO stock price?
Oruka Therapeutics ABIO stock price today per share is 28.8 USD.
How to purchase Oruka Therapeutics stock?
You can buy ABIO shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Oruka Therapeutics?
The stock symbol or ticker of Oruka Therapeutics is ABIO.
Which industry does the Oruka Therapeutics company belong to?
The Oruka Therapeutics industry is Biotechnology.
How many shares does Oruka Therapeutics have in circulation?
The max supply of Oruka Therapeutics shares is 1.21M.
What is Oruka Therapeutics Price to Earnings Ratio (PE Ratio)?
Oruka Therapeutics PE Ratio is 0.00000000 now.
What was Oruka Therapeutics earnings per share over the trailing 12 months (TTM)?
Oruka Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Oruka Therapeutics company belong to?
The Oruka Therapeutics sector is Healthcare.
Oruka Therapeutics ABIO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 18737.21 USD — |
-1
|
7.88B USD — | 18599.69 USD — | 18841.52 USD — | — - | 7.88B USD — |
| NASDAQ Composite Total Return XCMP | 22955.12 USD — |
-0.99
|
— — | 22786.65 USD — | 23082.91 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 112.43 USD — |
+0.26
|
— — | 109.69 USD — | 112.55 USD — | — - | — — |
| Nasdaq Health Care IXHC | 932.02 USD — |
-0.03
|
— — | 920.46 USD — | 933.54 USD — | — - | — — |
- {{ link.label }} {{link}}